http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0274916-A3
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-60 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23K1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23K1-165 |
| filingDate | 1987-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1989-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0274916-A3 |
| titleOfInvention | Grf analogs |
| abstract | The invention provides peptides which are npotent in stimulating the release of pituitary GH in nfish and amphibians which have a substantial portion or nall of the following sequence: R₁-R₂-R₃-R₄-R₅-nPhe-R₇-R₈-R₉-Tyr-Arg-R₁₂-R₁₃-Leu-R₁₅-Gln-LeuR₁₈-Ala-nArg-Lys-R₂₂-Leu-R₂₄-R₂₅-R₂₆-R₂₇-R₂₈-R₂₉-R₃₀-R₃₁-nGly-R₃₃-R₃₄-R₃₅-R₃₆-R-₃₇R-₃₈R-₃₉R-₄₀R-₄₁-R₄₂-nR₄₃-R₄₄-Ser wherein R₁ is N-Me Tyr, Tyr, ndesNH₂-Tyr, D-Tyr, N-Et Tyr, N-Ip Tyr, N-Me His, His, ndesNH₂-His, D-His, N-Et His, and N-Ip His; R₂ is nAla, D-Ala or D-NMA; R₃ is Asp or D-Asp; R₄ is Gly nor Ala; R₅ and R₂₇ are selected from the group nconsisting of Met, Leu, Val, Nva, Gln, Thr, Ile, Ala, nArg, Asn, Asp, Cys, Glu, Gly, His, Nle, Lys, Phe, Pro, nSer, Tyr and Trp; R₇ is Asn or Thr; R₈ is Lys, Asn nor Ser; R₉ is Ala or Ser; R₁₂ is Lys or Arg; R₁₃ nis Ala, Val or Ile; R₁₅ is Gly or Ala; R₁₈ is Ser or nTyr; R₂₂ is Tyr or Leu; R₂₄ is His or Gln; R₂₅ is nThr, Asp, or Glu; R₂₆ is Leu or Ile; R₂₈ is Ala, Ser nor Asn; R₂₉ is Lys or Arg; R₃₀ is Arg or Gln; R₃₁ nis Val or Gln; R₃₃ is Gly or Glu; R₃₄ is Gly, Arg or nSer; R₃₅ is Ser or Asn; R₃₆ is Met, Leu, Val, Nva, nGln, Thr, Ile or Nle; R₃₇ is Ile or Glu; R₃₈ is Glu, nGln or Arg; R₃₉ is Asp, Arg or Gly; R₄₀ is Asp, Ser nor Ala; R₄₁ is Asn, Arg or Lys; R₄₂ is Glu, Phe, Ala nor Val; R₄₃ is Pro, Asn or Arg; R₄₄ is Leu or Ala; nprovided however that at least one of the following is npresent: R₇ is Asn, R₈ is Lys, R₁₃ is Ala, R₂₂ nis Tyr and R₂₅ is Thr; and provided further that any nor all of the residues after R₂₇ may be deleted. A n29-residue peptide beginning at the N-terminus may be npreferred. These peptides, as well as their nontoxic nsalts, are considered to be particularly useful in nagriculture. |
| priorityDate | 1987-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.